1.
Cutaneous involvement of high-grade B-cell lymphoma with MYC and BCL6 rearrangements: A case report.
J Dermatol
; 50(8): e243-e244, 2023 08.
Article
in English
| MEDLINE
| ID: mdl-36890662
Subject(s)
Lymphoma, B-Cell , Lymphoma, Large B-Cell, Diffuse , Humans , Lymphoma, B-Cell/diagnosis , Lymphoma, B-Cell/genetics , Gene Rearrangement , Proto-Oncogene Proteins c-bcl-6/genetics , Proto-Oncogene Proteins c-bcl-2/genetics , Lymphoma, Large B-Cell, Diffuse/diagnosis , Lymphoma, Large B-Cell, Diffuse/genetics , Lymphoma, Large B-Cell, Diffuse/pathology , Proto-Oncogene Proteins c-myc/genetics
2.
J Dermatol
; 50(2): 254-257, 2023 Feb.
Article
in English
| MEDLINE
| ID: mdl-36317542
ABSTRACT
The most common treatment option for patients with bullous pemphigoid is systemic corticosteroids. CYP3A4, a drug-metabolizing enzyme in the liver, metabolizes synthetic steroids to a varying degree. Although there are many CYP3A4-inducing drugs, several antiepileptic drugs, such as phenytoin and phenobarbital, strongly induce CYP3A4, thereby reducing the effects of corticosteroids. Here, we report a case of refractory bullous pemphigoid that rapidly improved after the discontinuation of phenytoin and phenobarbital. To achieve adequate pharmacological effects of corticosteroids, we must always ensure that patients who require corticosteroids for treatment are not medicated with CYP3A4-inducing agents.
Subject(s)
Anticonvulsants , Pemphigoid, Bullous , Humans , Anticonvulsants/therapeutic use , Pemphigoid, Bullous/drug therapy , Cytochrome P-450 CYP3A/therapeutic use , Phenytoin/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Phenobarbital/therapeutic use
3.
J Dermatol
; 48(12): e594-e595, 2021 Dec.
Article
in English
| MEDLINE
| ID: mdl-34536237